GeoVax Advances GEO-MVA Phase 3 Trial as Mpox Vaccine Supply Concerns Persist
GeoVax reports first quarter 2026 financial results and details plans for a pivotal Phase 3 immunobridging study of its MVA-based mpox/smallpox vaccine, highlighting the strategic importance of diversifying orthopoxvirus vaccine supply amid global supply constraints.
GeoVax Labs, Inc. (Nasdaq: GOVX) reported financial results for the first quarter of 2026 and provided updates on its lead programs, emphasizing progress toward initiating a Phase 3 immunobridging clinical trial for GEO-MVA, its Modified Vaccinia Ankara (MVA) vaccine candidate for mpox and smallpox. The company is pursuing an expedited regulatory pathway aligned with guidance from the European Medicines Agency (EMA), which could accelerate regulatory authorization and commercialization.
“GeoVax has strategically aligned the organization around GEO-MVA and the significant global opportunity for a diversified MVA vaccine supply,” said David A. Dodd, Chairman and CEO. The company believes GEO-MVA is positioned at the intersection of global public health preparedness, biodefense resiliency, and domestic manufacturing priorities. The ongoing evolution of mpox, global supply constraints, and dependence on a single foreign supplier for MVA-based orthopoxvirus vaccines underscore the need for additional scalable supply sources.
Recent milestones include the completion and release of cGMP clinical trial material, selection of a CRO, and activation of trial infrastructure. The Phase 3 study is expected to enroll approximately 500 participants and will evaluate neutralizing antibody responses relative to an approved MVA comparator vaccine. The design aims to provide rapid clinical validation through established immunobridging endpoints. Additionally, GeoVax is advancing continuous cell-line manufacturing using the AGE1® platform to support future scalable MVA vaccine manufacturing capacity.
The company also highlighted its immuno-oncology program, Gedeptin®, a gene-directed enzyme prodrug therapy designed to enhance checkpoint inhibitor activity in solid tumors. GeoVax recently strengthened its intellectual property position through an exclusive license agreement with Emory University covering Gedeptin in combination with immune checkpoint inhibitors. “We believe the combination of GEO-MVA biosecurity preparedness and Gedeptin immunotherapy optionality positions GeoVax within two strategically important healthcare sectors,” Dodd added.
Financially, GeoVax reported a net loss of $5.3 million for the quarter ended March 31, 2026, compared to $5.4 million in the same period in 2025. Revenue from government contracts was $0 in the 2026 quarter, versus $1.6 million in the prior year, reflecting the termination of the BARDA/RRPV Project NextGen award for its COVID-19 vaccine program in April 2025. Research and development expenses decreased to $3.9 million from $5.4 million, primarily due to lower costs from discontinued BARDA activities. General and administrative expenses fell to $1.4 million from $1.7 million. Cash and cash equivalents stood at $1.3 million as of March 31, 2026, down from $3.1 million at year-end 2025.
GeoVax’s strategic prioritization of GEO-MVA reflects the convergence of established MVA platform validation, expedited regulatory alignment, large existing and anticipated orthopoxvirus vaccine demand, and growing interest in diversified vaccine supply chains. The company believes its immuno-oncology strategy may provide long-term optionality within the evolving checkpoint inhibitor landscape. For more information, visit www.geovax.com.